Citation Impact
Citing Papers
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 StandoutScience
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Tracking and Functional Characterization of Epithelial–Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis
2015
Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
2015
Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
2014
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
2014
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer
2015
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013
Breast cancer
2019 Standout
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
2015
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Aberrant intracellular metabolism of T‐ DM 1 confers T‐ DM 1 resistance in human epidermal growth factor receptor 2‐positive gastric cancer cells
2017
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985
2015
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
2013
Patient‐reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T‐DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2–positive locally advanced or metastatic breast cancer
2013
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
2014 Standout
Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
2008
Big data in biomedicine
2013
Cardiac side-effects of cancer chemotherapy
2010
Idiopathic pulmonary fibrosis
2017 Standout
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
2012 Standout
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
2013
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Evolving Strategies for Target Selection for Antibody-Drug Conjugates
2015
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
2013 Standout
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
2010
ROS in cancer therapy: the bright side of the moon
2020 Standout
Cardioncology: State of the heart
2013
Antibody-targeted drugs and drug resistance—Challenges and solutions
2014
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
The Thrombospondins
2011 Standout
Renal Effects of Anti-angiogenesis Therapy: Update for the Internist
2009
EMT Transition States during Tumor Progression and Metastasis
2018 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies
2009
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Cardiac Toxicity of Targeted Therapies Used in the Treatment for Solid Tumours: A Review
2012
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
2014
Circulating tumour cells in cancer patients: challenges and perspectives
2010
Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway
2015
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
2010
Management of hypertension in angiogenesis inhibitor-treated patients
2009
Chemotherapy-associated renal dysfunction
2009
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
2016
Emerging Biological Principles of Metastasis
2017 Standout
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Cardiovascular Complications of Cancer Therapy
2009
Targeting metastasis
2016
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension
2011
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
2010
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis
2013
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
2013 Standout
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
2010 Standout
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
2014
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
2018 StandoutNobel
Functional Roles of the IgM Fc Receptor in the Immune System
2019 StandoutNobel
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
2019
An Algorithm for the Management of Hypertension in the Setting of Vascular Endothelial Growth Factor Signaling Inhibition
2011
Cancer drugs and the heart: importance and management
2012
Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs
2016
ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats
2018 Standout
Incidence and risk of hypertension with a novel multi‐targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta‐analysis
2013
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
2009
Molecular Regulation of Tumor Angiogenesis and Perfusion via Redox Signaling
2009
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta‐analysis of clinical trials
2012
Sorafenib for the treatment of advanced hepatocellular carcinoma
2010
Epithelial Mesenchymal Transition in Tumor Metastasis
2018 Standout
Circulating tumor cells: approaches to isolation and characterization
2011
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
FRET Reagent Reveals the Intracellular Processing of Peptide-Linked Antibody–Drug Conjugates
2018
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
2010
Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
2012
COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention
2021
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials
2014
Cancer Genome Landscapes
2013 StandoutScience
Natural product and natural product derived drugs in clinical trials
2014 Standout
Formylglycine, a Post-Translationally Generated Residue with Unique Catalytic Capabilities and Biotechnology Applications
2014 StandoutNobel
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
2014
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
2015 Standout
MeDShare: Trust-Less Medical Data Sharing Among Cloud Service Providers via Blockchain
2017 Standout
Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles
2016
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Characterization of DNA Methylation in Circulating Tumor Cells
2015
2020 International Society of Hypertension Global Hypertension Practice Guidelines
2020 Standout
Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
2015
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Exploring the Interrelationship between COVID-19 Phobia, Work–Family Conflict, Family–Work Conflict, and Life Satisfaction among School Administrators for Advancing Sustainable Management
2021 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of Janice Lu being referenced
Targeted therapy for HER2 positive breast cancer
2013
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
2015
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients
2009
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
2008
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2013